Хатьков И.Е., Парфенов А.И., Князев О.В., Михайлянц Г.С., Атрощенко А.О., Ручкина И.Н. Воспалительные заболевания кишечника в практике терапевта и хирурга. М.: Вита-Пресс; 2017. 120 с.
Peyrin-Biroulet L., Sandborn W., Sands B.E., Reinisch W., Bemelman W., Bryant R.V. et al. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): determining therapeutic goals for treat-to-target. Am J Gastroenterol. 2015;110(9):1324–1338. https://doi.org/10.1038/ajg.2015.233..
DOI: 10.1038/ajg.2015.233
Travis S.P., Stange E.F., Lémann M., Oresland T., Bemelman W.A., Chowers Y. et al. European evidence-based Consensus on the management of ulcerative colitis: Current management. J Crohns Colitis. 2008;2(1):24–62. https://doi.org/10.1016/j.crohns.2007.11.002..
DOI: 10.1016/j.crohns.2007.11.002
Ford A.C., Achkar J.P., Khan K.J., Kane S.V., Talley N.J., Marshall J.K., Moayyedi P. Efficacy of 5-aminosalicylates in ulcerative colitis: systematic review and meta-analysis. Am J Gastroenterol. 2011;106(4):601–616. https://doi.org/10.1038/ajg.2011.67..
DOI: 10.1038/ajg.2011.67
Ham M., Moss A.C. Mesalamine in the treatment and maintenance of remission of ulcerative colitis. Expert Rev Clin Pharmacol. 2012;5(2):113–123. https://doi.org/10.1586/ecp.12.2..
DOI: 10.1586/ecp.12.2
Wang Y., Parker C.E., Feagan B.G., MacDonald J.K. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2016;2016(5):CD000544. https://doi.org/10.1002/14651858.CD000544.pub4..
DOI: 10.1002/14651858.CD000544.pub4
Kruis W., Jonaitis L., Pokrotnieks J., Mikhailova T.L., Horynski M., Bátovský M. et al. Randomised clinical trial: a comparative dose-finding study of three arms of dual release mesalazine for maintaining remission in ulcerative colitis. Aliment Pharmacol Ther. 2011;33(3):313–322. https://doi.org/10.1111/j.1365-2036.2010.04537.x..
DOI: 10.1111/j.1365-2036.2010.04537.x
Nagahori M., Kochi S., Hanai H., Yamamoto T., Nakamura S., Omuro S. et al. Real life results in using 5-ASA for maintaining mild to moderate UC patients in Japan, a multi-center study, OPTIMUM Study. BMC Gastroenterol. 2017;17(1):47. https://doi.org/10.1186/s12876-017-0604-y..
DOI: 10.1186/s12876-017-0604-y
D’Incà R., Paccagnella M., Cardin R., Pathak S., Baldo V., Giron M.C., Sturniolo G.C. 5-ASA colonic mucosal concentrations resulting from different pharmaceutical formulations in ulcerative colitis. World J Gastroenterol. 2013;19(34):5665–5670. https://doi.org/10.3748/wjg.v19.i34.5665..
DOI: 10.3748/wjg.v19.i34.5665
Tenjarla S., Abinusawa A. In-vitro characterization of 5-aminosalicylic acid release from MMX mesalamine tablets and determination of tablet coating thickness. Adv Ther. 2011;28(1):62–72. https://doi.org/10.1007/s12325-010-0087-5..
DOI: 10.1007/s12325-010-0087-5
Nardelli S., Pisani L.F., Tontini G.E., Vecchi M., Pastorelli L. MMX® technology and its applications in gastrointestinal diseases. Therap Adv Gastroenterol. 2017;10(7):545–552. https://doi.org/10.1177/1756283X17709974..
DOI: 10.1177/1756283X17709974
Brunner M., Greinwald R., Kletter K., Kvaternik H., Corrado M.E., Eichler H.G., Müller M. Gastrointestinal transit and release of 5-aminosalicylic acid from 153Sm-labelled mesalazine pellets vs. tablets in male healthy volunteers. Aliment Pharmacol Ther. 2003;17(9):1163–1169. https://doi.org/10.1046/j.1365-2036.2003.01564.x..
DOI: 10.1046/j.1365-2036.2003.01564.x
Prantera C., Viscido A., Biancone L., Francavilla A., Giglio L., Campieri M. A new oral delivery system for 5-ASA: preliminary clinical findings for MMx. Inflamm Bowel Dis. 2005;11(5):421–427. https://doi.org/10.1097/01.mib.0000158386.25660.1e..
DOI: 10.1097/01.mib.0000158386.25660.1e
Fiorino G., Fries W., De La Rue S.A., Malesci A.C., Repici A., Danese S. New drug delivery systems in inflammatory bowel disease: MMX and tailored delivery to the gut. Curr Med Chem. 2010;17(17):1851–1857. https://doi.org/10.2174/092986710791111170..
DOI: 10.2174/092986710791111170
Lichtenstein G.R., Kamm M.A., Boddu P., Gubergrits N., Lyne A., Butler T. et al. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. Clin Gastroenterol Hepatol. 2007;5(1):95–102. https://doi.org/10.1016/j.cgh.2006.10.025..
DOI: 10.1016/j.cgh.2006.10.025
Kamm M.A., Sandborn W.J., Gassull M., Schreiber S., Jackowski L., Butler T. et al. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology. 2007;132(1):66–75. https://doi.org/10.1053/j.gastro.2006.10.011..
DOI: 10.1053/j.gastro.2006.10.011
Sandborn W.J., Kamm M.A., Lichtenstein G.R., Lyne A., Butler T., Joseph R.E. MMX Multi Matrix System mesalazine for the induction of remission in patients with mild-to-moderate ulcerative colitis: a combined analysis of two randomized, double-blind, placebo-controlled trials. Aliment Pharmacol Ther. 2007;26(2):205–215. https://doi.org/10.1111/j.1365-2036.2007.03361.x.
DOI: 10.1111/j.1365-2036.2007.03361.x
Prantera C., Kohn A., Campieri M., Caprilli R., Cottone M., Pallone F. et al. Clinical trial: ulcerative colitis maintenance treatment with 5-ASA: a 1-year, randomized multicentre study comparing MMX with Asacol. Aliment Pharmacol Ther. 2009;30(9):908–918. https://doi.org/10.1111/j.1365-2036.2009.04117.x..
DOI: 10.1111/j.1365-2036.2009.04117.x
Князев О.В., Каграманова А.В., Лищинская А.А. Оценка эффективности терапии язвенного колита средней степени тяжести месалазином ММХ. Медицинский совет. 2021;(5):113–123. https://doi.org/10.21518/2079-701X-2021-5-113-123..
DOI: 10.21518/2079-701X-2021-5-113-123
Cuomo A., Sgambato D., D’Auria M.V., Miranda A., Ferrante E., Romano M. Multi matrix system mesalazine plus rectal mesalazine in the treatment of mild to moderately active ulcerative proctitis. Dig Dis. 2018;36(2): 130–135. https://doi.org/10.1159/000485614..
DOI: 10.1159/000485614
Ивашкин В.Т., Шелыгин Ю.А., Белоусова Е.А., Абдулганиева Д.И., Алексеева О.А., Ачкасов С.И. и др. Проект клинических рекомендаций по диагностике и лечению язвенного колита. Колопроктология. 2019;18(4):7–36. https://doi.org/10.33878/2073-7556-2019-18-4-7-36..
DOI: 10.33878/2073-7556-2019-18-4-7-36
Schroeder K.W., Tremaine W.J., Ilstrup D.M. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987;317(26):1625–1629. https://doi.org/10.1056/NEJM198712243172603..
DOI: 10.1056/NEJM198712243172603
Morisky D.E., Green L.W., Levine D.M. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986;24(1):67–74. https://doi.org/10.1097/00005650-198601000-00007..
DOI: 10.1097/00005650-198601000-00007
Trindade A.J., Ehrlich A., Kornbluth A., Ullman T.A. Are your patients taking their medicine? Validation of a new adherence scale in patients with inflammatory bowel disease and comparison with physician perception of adherence. Inflamm Bowel Dis. 2011;17(2):599–604. https://doi.org/10.1002/ibd.21310..
DOI: 10.1002/ibd.21310
Gionchetti P., Rizzello F., Venturi A., Ferretti M., Brignola C., Miglioli M., Campieri M. Comparison of oral with rectal mesalazine in the treatment of ulcerative proctitis. Dis Colon Rectum. 1998;41(1):93–97. https://doi.org/10.1007/BF02236902..
DOI: 10.1007/BF02236902
Kam L., Cohen H., Dooley C., Rubin P., Orchard J. A comparison of mesalamine suspension enema and oral sulfasalazine for treatment of active distal ulcerative colitis in adults. Am J Gastroenterol. 1996;91(7): 1338–1342. Available at: https://pubmed.ncbi.nlm.nih.gov/8677990/.https://pubmed.ncbi.nlm.nih.gov/8677990/
Kam L., Cohen H., Dooley C., Rubin P., Orchard J. A comparison of mesalamine suspension enema and oral sulfasalazine for treatment of active distal ulcerative colitis in adults. Am J Gastroenterol. 1996;91(7): 1338–1342. Available at: https://pubmed.ncbi.nlm.nih.gov/8677990/.https://pubmed.ncbi.nlm.nih.gov/8677990/
Safdi M., DeMicco M., Sninsky C., Banks P., Wruble L., Deren J. et al. A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. Am J Gastroenterol. 1997;92(10):1867–1871. Available at: https://pubmed.ncbi.nlm.nih.gov/9382054/.https://pubmed.ncbi.nlm.nih.gov/9382054/
Safdi M., DeMicco M., Sninsky C., Banks P., Wruble L., Deren J. et al. A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. Am J Gastroenterol. 1997;92(10):1867–1871. Available at: https://pubmed.ncbi.nlm.nih.gov/9382054/.https://pubmed.ncbi.nlm.nih.gov/9382054/
Richter J.M., Arshi N.K., Oster G. Oral 5-aminosalicylate, mesalamine suppository, and mesalamine enema as initial therapy for ulcerative proctitis in clinical practice with quality of care implications. Can J Gastroenterol Hepatol. 2016:6928710. https://doi.org/10.1155/2016/6928710..
DOI: 10.1155/2016/6928710
Brunner M., Lackner E., Exler P.S., Fluiter H.C., Kletter K., Tschurlovits M. et al. 5-aminosalicylic acid release from a new controlled-release mesalazine formulation during gastrointestinal transit in healthy volunteers. Aliment Pharmacol Ther. 2006;23(1):137–144. https://doi.org/10.1111/j.1365-2036.2006.02721.x..
DOI: 10.1111/j.1365-2036.2006.02721.x
Wilding I.R., Behrens C., Tardif S.J., Wray H., Bias P., Albrecht W. Combined scintigraphic and pharmacokinetic investigation of enteric-coated mesalazine micropellets in healthy subjects. Aliment Pharmacol Ther. 2003;17(9):1153–1162. https://doi.org/10.1046/j.1365-2036.2003.01558.x..
DOI: 10.1046/j.1365-2036.2003.01558.x
Sciarretta G., Furno A., Mazzoni M., Ferrieri A., Malaguti P. Scintigraphic study of gastrointestinal transit and disintegration sites of mesalazine tablets labeled with technetium-99m. Scand J Gastroenterol. 1993;28(9):783–785. https://doi.org/10.3109/00365529309104009..
DOI: 10.3109/00365529309104009
Парфенов А.И., Князев О.В., Бабаян А.Ф., Каграманова А.В. Низкая приверженность лечению – слабое звено в цепи проблем язвенного колита. Терапевтический архив. 2021;93(12):1419–1427. https://doi.org/10.26442/00403660.2021.12.201172..
DOI: 10.26442/00403660.2021.12.201172
Chowdhury R., Khan H., Heydon E., Shroufi A., Fahimi S., Moore C. et al. Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences. Eur Heart J. 2013;34(38):2940–2948. https://doi.org/10.1093/eurheartj/eht295..
DOI: 10.1093/eurheartj/eht295
Harbord M., Eliakim R., Bettenworth D., Karmiris K., Katsanos K., Kopylov U. et al. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management. J Crohns Colitis. 2017;11(7):769–784. https://doi.org/10.1093/ecco-jcc/jjx009..
DOI: 10.1093/ecco-jcc/jjx009
Kane S.V., Cohen R.D., Aikens J.E., Hanauer S.B. Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. Am J Gastroenterol. 2001;96(10):2929–2933. https://doi.org/10.1111/j.1572-0241.2001.04683.x..
DOI: 10.1111/j.1572-0241.2001.04683.x
Loftus E.V. Jr. A practical perspective on ulcerative colitis: patients’ needs from aminosalicylate therapies. Inflamm Bowel Dis. 2006;12(12):1107– 1113. https://doi.org/10.1097/01.mib.0000235831.01682.8d..
DOI: 10.1097/01.mib.0000235831.01682.8d
Moody G.A., Jayanthi V., Probert C.S., Mac Kay H., Mayberry J.F. Longterm therapy with sulphasalazine protects against colorectal cancer in ulcerative colitis: a retrospective study of colorectal cancer risk and compliance with treatment in Leicestershire. Eur J Gastroenterol Hepatol. 1996;8(12):1179–1183. https://doi.org/10.1097/00042737-199612000-00009..
DOI: 10.1097/00042737-199612000-00009
Shale M.J., Riley S.A. Studies of compliance with delayed-release mesalazine therapy in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2003;18(2):191–198. https://doi.org/10.1046/j.1365-2036.2003.01648.x..
DOI: 10.1046/j.1365-2036.2003.01648.x